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Abstract
Background The effectiveness of adjunctive perampanel has not been systematically assessed in seizure types other than 
its approved indications of focal seizures and primary generalised tonic–clonic seizures (PGTCS) in idiopathic generalised 
epilepsies (IGEs).
Objective We aimed to identify and review available evidence on outcomes with perampanel in generalised seizures and 
epilepsies to examine its potential as a broad-spectrum anti-seizure medication.
Methods Bibliographic databases of publications, clinical trials, and conference abstracts were searched up to August 2020 to 
identify studies reporting seizure or safety outcomes in patients of any age, with any type of epilepsy-associated generalised 
seizures treated with perampanel. Data extracted from selected records were tabulated by seizure type and syndrome, and 
analysed qualitatively (PROSPERO protocol CRD42020201564).
Results Ninety-one reports met inclusion criteria and were selected: 15 reports of 1 randomised controlled trial (RCT), 8 
reports of 4 non-randomised interventional studies, 37 reports of observational studies, 21 case reports and 10 systematic 
reviews and meta-analyses. Extracted data included 359 patients with PGTCS of any aetiology, 251 with myoclonic seizures, 
112 with absence seizures, 50 with tonic seizures and 32 children with epileptic spasms. The most commonly reported epi-
lepsy type was IGE (N = 378) and the most common syndromes were juvenile myoclonic epilepsy (N = 92), progressive 
myoclonic epilepsies (N = 59) and absence epilepsies (N = 43). The RCT provided Class I evidence of the efficacy and toler-
ability of adjunctive perampanel for PGTCS in patients aged ≥ 12 years with IGE. Data from other studies provides weaker 
(observational) evidence of its effectiveness in multiple generalised seizure types, including myoclonic, absence and tonic 
seizures. There were no patterns suggesting seizure worsening or aggravation in any seizure or epilepsy type.
Conclusions The identified studies suggest the potential of perampanel as a broad-spectrum antiseizure medication. Much 
of the available data, however, come from non-randomised, non-controlled studies and are open to high risk of bias. Further 
studies are warranted to provide more robust evidence.
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1 Introduction
Epilepsies are one of the most common chronic disorders of 
the brain, and pharmacotherapy with anti-seizure medica-
tions (ASMs) is central to management. Each ASM has a 
unique profile and needs to be tailored to individual patient 
factors, including the characteristics of seizures and specific 
epilepsy syndrome. Some ASMs have emerged as particu-
larly effective in treating specific seizure types or specific 
syndromes, but may be less effective in other seizure types 
or even precipitate or worsen seizures in certain syndromes. 
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Key Points 
Broad-spectrum anti-seizure medications are effective 
against focal and generalised seizures of any type and do 
not cause seizure aggravation.
We systematically searched and evaluated data about 
efficacy and safety of perampanel in generalised seizures.
Strong evidence supports the efficacy of perampanel in 
tonic–clonic seizures in idiopathic generalised epilepsy.
Observational studies suggest (with high risk of bias) 
effectiveness in myoclonic, absence and tonic seizures, 
and generalised epilepsy syndromes.
We found no evidence to suspect an association between 
perampanel and seizure worsening in generalised epilep-
sies.
or safety outcomes for patients of any age with epilepsy-
associated generalised seizures treated with perampanel.
2  Methods
The report of this systematic review was made according 
to the recommendations of the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) 
statement [4] and the Synthesis Without Meta-analysis in 
systematic reviews (SWiM) extension [5]. The study pro-
tocol was registered with the international prospective 
register of systematic reviews (PROSPERO; reference 
CRD42020201564), and this database was checked to ensure 
a similar review was not already underway.
We use the term ‘generalised seizure’ (occasionally ‘gen-
eralised-onset’ to avoid ambiguity) to indicate seizures with 
generalised onset, according to the ILAE 2017 classifica-
tion of the epilepsies and seizure types [6, 7]. Terminology 
is therefore not always consistent with the source articles, 
which used variable terms and often used ‘generalised’ to 
refer to focal-to-bilateral tonic–clonic seizures.
2.1  Information Sources and Search Terms
We systematically searched electronic literature databases, 
conference databases, clinical trials databases between July 
and August 2020, and scanned reference lists of retrieved 
articles (December 2020). No language or date restrictions 
were applied, and English-language abstracts were used if 
authors were not proficient enough in the published language 
to screen for inclusions or extract relevant data. Abstracts at 
key epilepsy conferences were included (American Acad-
emy of Neurology [AAN], American Epilepsy Society 
[AES], European Academy of Neurology [EAN], European 
Congress on Epileptology [ECE] and International Epilepsy 
Congress [IEC]). Broad search terms were used (‘peram-
panel’, ‘fycompa’ and ‘E2007’) to identify studies of any 
type or design that reported outcomes in patients receiving 
perampanel (see electronic supplementary material ESM 1, 
Appendix A, for full details).
2.2  Eligibility Criteria
Studies of any type were eligible, including randomised, 
double-blind, controlled trials; randomised, open-label tri-
als; non-randomised trials; observational studies (defined 
as data collected as part of routine care, in a defined popu-
lation of patients receiving perampanel) and case series or 
case reports (defined as observational reports in a subset of 
patients or selected individual receiving perampanel).
Studies had to include patients with epilepsy-associ-
ated generalised seizure types, generalised epilepsies or 
ASMs are considered ‘broad-spectrum’ when they are effec-
tive against focal and generalised seizures of any type and 
do not usually cause seizure aggravation [1].
Perampanel is a selective non-competitive antagonist of 
the glutamate AMPA receptor ion channel that has been 
approved as adjunctive treatment of focal seizures in patients 
aged ≥ 4 years (and as monotherapy in the USA), and as 
adjunctive treatment of primary generalised tonic–clonic 
seizures (PGTCS) associated with idiopathic generalised 
epilepsy (IGE) in patients aged ≥ 12 years (and ≥ 7 years 
in the EU), on the basis of Class I evidence in patients aged 
≥ 12 years [2, 3]. The effectiveness of perampanel in other 
generalised seizure types, and therefore whether it can be 
considered a broad-spectrum ASM, has not been systemati-
cally assessed.
The limited choice of broad-spectrum ASMs available, 
the serious nature of some seizure types, and the limited 
amount of high-quality data from randomised controlled 
trials (RCTs) led us to seek and evaluate all available data, 
include evidence from study types open to bias. Real-world 
evidence from observational studies can complement data 
from RCTs, and has value for understanding outcomes in 
routine clinical practice. This is particularly important for 
patient populations that are left out of RCTs, such as people 
with intellectual disability, in whom epilepsy is common. 
In these populations, real-world evidence may be the only 
available evidence. We feel the value of including a large 
quantity of data from observational, uncontrolled trials and 
case reports outweighs the limitations in interpreting such 
data and the weak certainty of conclusions.
To examine whether perampanel can be considered a 
broad-spectrum ASM, we systematically searched for studies 
of any type that reported clinical data on seizure outcomes 
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generalised epilepsy syndromes who received oral peram-
panel as either adjunctive therapy or monotherapy. Partici-
pants of any age, sex, and ethnicity were eligible. Studies 
that included participants with exclusively non-epileptic 
seizure types (e.g. post-hypoxic seizures), exclusively non-
generalised-onset seizure types, status epilepticus, or acute 
symptomatic seizures were excluded.
2.3  Outcome Measures
The core seizure outcome measures were change in seizure 
frequency relative to baseline, 50% responder rate (propor-
tion of patients with ≥ 50% reduction in baseline seizure 
frequency) and seizure freedom. We also collected other rel-
evant seizure data, including subjective and objective change 
in seizure severity relative to baseline, seizure worsening or 
aggravation and functional outcomes associated with seizures 
(e.g. activities of daily living). Retention rate (proportion of 
patients continuing on perampanel at endpoint, as a proportion 
of all those who started perampanel) was also recorded. We 
expected definitions of seizure outcomes to differ across stud-
ies, and we recorded data as reported in data extraction tables.
Safety outcomes included overall incidence of adverse 
events (AEs), the rate of individual AEs, AEs leading to dis-
continuation and AEs indicative of seizure worsening (e.g. 
status epilepticus, seizure clusters).
Reports that included patients with generalised seizures/
epilepsy types but that did not report seizure or safety out-
comes for generalised seizures separately from focal seizures 
were excluded. Only safety data (not seizure outcome data) 
were extracted from open-label extension (OLEx) studies of 
randomised controlled trials.
2.4  Study Selection, Data Extraction 
and Assessment of Risk of Bias
Two review authors (FR and BN) independently screened 
abstracts identified through searches of literature and confer-
ence databases to identify potentially relevant reports. Con-
ference abstracts were further screened by KC and RW to 
remove duplicates (including unique but ‘encore’ abstracts 
that contained the same data as other abstracts), abstracts 
superseded by publications, and abstracts reporting interim 
data superseded by later reports.
KC screened results from clinical trials database searches, 
removed duplicates, and contacted study sponsors to request 
data (or interim data) for completed (and ongoing) studies.
Two authors (SL and TC) independently reviewed full 
texts of screened results and selected relevant reports for 
inclusion; RW and KC checked selections and any disagree-
ment was resolved through discussion with a third review 
author (ET). FB, FR and BN manually searched reference 
lists of included studies for additional relevant reports.
RW extracted relevant data into Excel spreadsheets (Sup-
plemental Table S1, see ESM 4) by study type (RCTs, non-
randomised interventional trials, observational studies, case 
reports/series), and ordered by study size; KC checked accu-
racy of data extraction. The extracted variables included study 
authors, date of publication, number and top-line demograph-
ics of overall participants, dosing of perampanel, seizure out-
comes and safety data in any generalised seizure populations 
or subpopulations (Supplemental Table S1, see ESM 4).
The risk of bias (RoB) of the included RCTs was assessed 
at the outcome level using the RoB 2 tool [8] by RS and RW; 
ET arbitrated any differences (Supplementary information: 
Appendix E, see ESM 2). RoB was not assessed individually 
for other study types (observational cohort studies and case 
reports). Instead, these study types were considered at high 
risk of bias and their data and conclusions were interpreted 
accordingly.
2.5  Data Synthesis
Data synthesis was qualitative, not quantitative, because of 
the anticipated heterogeneity of study designs and outcomes 
data collected. The aim of the synthesis strategy was to 
identify patterns that could suggest beneficial effect, lack of 
effect, or seizure worsening with perampanel in specific sei-
zure types or syndromes. Therefore, data were tabulated for 
generalised epilepsy overall and then separately by seizure 
type and syndrome (where sufficient data were available), 
and grouped into summary tables giving the range of values. 
Because of heterogeneity in design of the included stud-
ies, data from different study types were listed separately, 
and data from case reports were not grouped or synthesised. 
Because of the preliminary and non-peer-reviewed nature of 
conference abstracts, these were reported separately from 
published, peer-reviewed literature.
3  Results
3.1  Study Selection
Database searches returned 2820 results (2419 from litera-
ture databases, 273 from conference proceedings, 128 from 
clinical trials databases); no additional records were identi-
fied in manual searches of reference lists. Relevant data was 
extracted from 91 items (Fig. 1).
3.2  Study Characteristics
Characteristics of all selected studies are shown in Appendix 
B of the ESM 1.
One randomised, double-blind, placebo-controlled, 
parallel-group trial was identified. It recruited patients 
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aged ≥ 12 years with independently confirmed refractory 
PGTCS associated with IGE (ClinicalTrials.gov identi-
fier: NCT01393743). In addition to its primary report [3], 
four secondary publications and nine conference abstracts 
reported extractable data from subgroup analyses and long-
term extension(s) (including NCT02427607, an OLEx 
in Japan), often pooled with other studies (Supplemental 
Table S2, see ESM 1).
Four non-randomised interventional studies were identi-
fied, reported in four full publications and four conference 
abstracts (Supplemental Table S3, see ESM 1).
Thirty-seven observational studies were identified; 23 
from published literature (Supplemental Table S4a, see 
ESM 1), of which six were in predominantly paediatric pop-
ulations, and 14 from conference abstracts (Supplemental 
Table S4b, see ESM 1), of which five were in predominantly 
paediatric populations.
Twenty-one reports of case studies were identified, 16 
from published literature and five from conference abstracts 
(Supplemental Table S5, see ESM 1); most were focused on 
effectiveness in rare epilepsy types, and three focused on AEs.
3.3  Risk of Bias
The RCT [3] was judged to have a low risk of bias over-
all and for each domain assessed by the tool (bias arising 
Fig. 1  PRISMA flow chart. 
Illustration of search results, 
screening and selection. Data-
base searches returned 2820 
results (2419 from literature 
databases, 273 from confer-
ence proceedings, 128 from 
clinical trials databases); 
no additional records were 
identified in manual searches 
of reference lists. Relevant data 
was extracted from 91 items. 
aOne full-text article was in a 
language not spoken by authors 
or contributors but had an 
abstract in English from which 
relevant data could be extracted 
[24]. bIncludes nine system-
atic reviews or meta-analyses. 
cIncludes one systematic review. 
PRISMA preferred reporting 
items for systematic reviews and 
meta-analyses, RCT randomised 















Full-text arcles excluded: n=233
Reasons for exclusion
n=28 Not relevant seizure types
n=64 Primary generalised seizure data not reported separately
n=48 Number of paents with primary generalised seizures 
not reported for outcomes of interest
n=16 No seizure or safety outcomes related to perampanel 
n=4 Not in a language spoken by authors or contributors
n=4 Perampanel overdose or accidental ingeson
n=4 Narrave review
n=4 Methods/protocol only
n=17 Superseded by later publicaon or later abstract 
n=16 Duplicate
n=6 Modeling analysis
n=5 OLEx study with no safety data for relevant seizure groups
n=1 Relevant data previously published
n=8 Study ongoing, no data available
n=2 Study completed but no data available














Included results by study type 
(total 91 results)
RCTs: 15 results (of 1 RCT)
Non-randomised intervenonal studies: 
8 results (of 4 studies)
Observaonal studies: 37 results
Case reports: 21 results
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from the randomisation process, due to deviations from the 
intended interventions, due to missing outcome data, in 
measurement of the outcome, in selection of the reported 
results) for the outcomes of retention rate, median percent 
change in PGTCS frequency per 28 days, 50% responder rate 
for PGTCS, and seizure-freedom rate for PGTCS (Appendix 
E, see ESM 2). The non-randomised interventional studies 
and observational studies were all assumed to have a high 
risk of bias and possible overestimation of efficacy, because 
of the lack of a control group and blinding/masking; in addi-
tion, the retrospective design of many of the observational 
studies increases the risk of bias.
3.4  Results of Individual Studies
3.4.1  Randomised, Double‑Blind, Placebo‑Controlled, 
Parallel Group Clinical Trial
The primary report from the identified RCT (NCT01393743; 
study 332) showed significantly greater reduction in seizure 
frequency in patients treated with adjunctive perampanel 
versus placebo-treated patients for PGTCS and for all sei-
zures, significantly greater responder rate for PGTCS, and 
numerically greater seizure-free rate for PGTCS and for all 
seizures (no statistical comparison) [3]. Incidence of sei-
zure worsening was not reported as an efficacy outcome, 
but AEs suggestive of seizure worsening were infrequent 
(Supplemental Table  S1, see ESM 4). Overall rates of 
treatment-emergent AEs (TEAEs) were higher in the per-
ampanel group than placebo, and the most common TEAEs 
were dizziness, fatigue, headache, somnolence and irrita-
bility. TEAEs suggestive of seizure worsening occurred in 
one patient in each group (severe status epilepticus with 
perampanel 6 mg/day, which resolved on discontinuation; 
moderate status epilepticus with placebo).
One post-hoc analysis of this phase III study explored 
outcomes by seizure type (Sect. 3.5.1.2–3, Supplemental 
Tables S6 and S7, see ESM 1). The other analyses added 
little information relevant to our objective; except for an 
apparently lower efficacy in the few patients taking concomi-
tant enzyme-inducing ASMs, seizure and safety outcomes 
were broadly consistent regardless of age, age at diagnosis, 
concomitant ASMs, and ethnicity in patients with PGTCS 
associated with IGE (see Supplemental Table S1 and Appen-
dix C in the ESM 1 for full details and references).
3.4.2  Non‑Randomised Interventional Studies
In paediatric patients, two prospective, open-label, multi-
centre studies had extractable outcome data in generalised 
seizures: Study 311 (NCT02849626) [9] and Study 232 
(NCT01527006) [10]. In Study 311, from a population 
of 180 patients aged 4 to < 12 years with focal seizure or 
PGTCS, 31 patients had generalised seizures, and among 
the 22 with PGTCS at baseline, seizure frequency was 
reduced by a median of 69% (95% CI 18–100; IQR 82) [9]. 
The responder rate for PGTCS was 64.0% (14/22) and the 
seizure-free rate for PGTCS was 55% at 23 weeks (12/22). 
Outcomes were not reported for other generalised seizure 
types. TEAEs were reported in 84% (26/31), serious TEAEs 
in 13% (4/31) and the most common TEAEs were somno-
lence (5/31), dizziness (5/31) and irritability (5/31). Three 
patients recorded serious TEAEs possibly suggestive of sei-
zure worsening (one had ‘petit mal epilepsy’; one ‘epilepsy’; 
one ‘seizure’ and ‘seizure cluster’). Extension data and anal-
yses by subgroups (age, number of concomitant ASMs, and 
IGE versus non-IGE) were broadly consistent with results 
for the overall generalised seizure population, but numbers 
were small (Supplemental Tables S8 and S9, see ESM 1).
In study 232, of 50 patients aged ≥ 2 to < 12 years, 22 
had generalised seizures, with a median 35.8% reduction 
in overall seizure frequency and a responder rate of 59.1% 
in the 11-week core study treatment phase. Seizure data 
were presented by age subgroups for these 50 patients, but 
with small numbers and highly variable data (Supplemental 
Tables S8 and S9, see ESM 1) [10]. Safety outcomes were 
not reported for the generalised seizure subgroup.
Two prospective studies in non-paediatric populations 
were identified. In 49 people (mean age 36.6 years) with pro-
gressive myoclonus epilepsy (PME) of various aetiologies, 
46.7% of patients (21/45) were classed as having improved 
myoclonic seizures (those with ≥ 1-point improvement in 
minimal myoclonus scale [MMS]), and 100% of patients 
(17/17) were classed as responders for PGTCS (≥ 50% 
reduction from baseline in PGTCS frequency, in patients 
with ≥ 2 PGTCS/month at baseline) [11]. In 10 people 
aged 15–41 years with Lafora disease, 3/7 (42.9%) reported 
reduction in myoclonic seizure frequency and 4/6 (66.7%) in 
PGTCS frequency; worsening of PGTCS frequency occurred 
in 2/6 (33.3%) (Supplemental Tables S8 and S9, see ESM 
1) [12].
3.4.3  Observational Studies
We identified reports in 257 patients of predominantly pae-
diatric ages who received perampanel (182 in published lit-
erature and 75 in conference abstracts). The largest observa-
tional study with perampanel in paediatric patients (Hwang 
et al.) reported data for 118 patients in generalised seizures, 
but no breakdown by seizure type or syndrome [13].
Other reports included data in smaller paediatric popu-
lations, with sample sizes ranging from 5 to 25 patients in 
generalised epilepsy, Dravet syndrome, lissencephaly, Len-
nox Gastaut syndrome (LGS), severe epileptic encephalopa-
thies, and juvenile myoclonic epilepsy (JME) (Supplemental 
Table S1 and Appendix C, see ESM 1).
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We identified reports in 692 adult patients and mixed-age 
populations treated with perampanel (548 in published lit-
erature and 144 patients in conference abstracts). The largest 
study (Villanueva et al.) provided outcomes by seizure type 
and syndrome in 149 patients aged ≥12 years with IGE, 
including JME, childhood absence epilepsy (CAE), juvenile 
absence epilepsy (JAE), and GTCS alone [14]. Other pub-
lications reported data in smaller adult/mixed populations, 
with sample sizes ranging from 8 to 114 patients, including 
those with refractory myoclonic epilepsies and PMEs (Sup-
plemental Table S1 and Appendix C, see ESM 1).
3.4.4  Case Studies/Series
Case studies and case series in 24 patients were identified 
and are listed in Supplemental Table S5, with full details in 
Supplemental Table S1 (see ESM 4).
3.4.5  Meta‑Analyses
We identified nine published systematic reviews and meta-
analyses and one conference abstract reporting a systematic 
review, which did not provide any additional data as the 
studies they identified had already been captured by our 
searches (Appendix C, see ESM 1).
3.5  Synthesis of Results
3.5.1  Outcomes by Seizure Type
3.5.1.1 PGTCS Outcomes for PGTCS are reported for 81 
people treated with perampanel in one RCT, 54 people in 
three non-randomised interventional studies, 215 people in 
14 observational studies, and nine people in case studies 
(total N = 359) (Table 1).
Studies included populations with different baseline 
characteristics and wide levels of refractoriness, and the 
responder rates ranged from 14% in highly refractory paedi-
atric populations [15] to 100% in a small population of JME 
patients [16]. In the largest studies of routine perampanel 
use, responder rates were generally > 50%, and freedom 
from PGTCS was reported in 63% of 115 patients with IGE 
in the study with the largest sample size [14].
3.5.1.2 Myoclonic Seizures Outcomes for myoclonic sei-
zures are reported for 24 people with myoclonic seizures 
associated with IGE in a post-hoc analysis of the RCT 
[17], in 59 patients treated with perampanel in two non-
randomised interventional studies [11, 12] and 151 patients 
in 14 observational studies (Table  2). These included 66 
patients with IGE (mostly JME) [14, 16, 18], 76 patients 
with PMEs [11, 12, 18–20] and three with Dravet syndrome 
[21].
The 17 case studies included 13 cases of PMEs [22–32], 
one of JME [33], one of graft versus host disease [34] and 
one patient with Angelman syndrome [29] (total N = 251) 
(Table 2).
In a post-hoc analysis of the RCT, seizure outcomes in 
24 patients with myoclonic seizures were explored [17]. 
Results were inconclusive, as the study was designed to 
assess changes in PGTCS frequency and did not have suffi-
cient statistical power to identify statistically significant dif-
ferences in the frequency of myoclonic seizures between the 
treatment arms. With small group sizes (perampanel N = 24, 
placebo N = 23), imbalance in demographic and prognostic 
factors is possible. Further, seizure frequency may be an 
appropriate outcome measure for PGTCS but cannot always 
be counted accurately for myoclonic seizures. The median 
frequency of myoclonic seizures at baseline was 13.8 in the 
perampanel group (range 0.5–719.9 per 28 days), and 3.5 in 
the placebo group (range 0.5–250.5 per 28 days). Freedom 
from myoclonic seizures was reported in 16.7% of patients 
(4/24) in the perampanel group and 13.0% (3/23) in the 
placebo group, and increased myoclonic seizure frequency 
was reported in 29.2% (7/24; perampanel) and 30.4% (7/23; 
placebo) (Supplemental Tables S6 and S7, see ESM 1) [17].
In the largest observational cohort of patients with myo-
clonic seizures (N = 48 with IGE), there was a mean 65% 
reduction in days with myoclonic seizures 1 year after addi-
tion of perampanel, and 65% of patients were free of myo-
clonic seizures [14]. Data on myoclonic seizure worsening 
were reported in six studies; four reported no worsening, 
one reported worsening in one out of three patients, and one 
reported physician-assessed worsening of intensity/duration 
in 1/46 patients at 12 months and increase in days with myo-
clonic seizures in 3/48 patients (6.3%) at 12 months [14]. 
Some of these studies also recorded functional improve-
ments (e.g. in speech, eating, movement) and improve-
ments in activities of daily living (Supplemental Table S1, 
see ESM 4) [18, 19, 35].
Case studies reported improvement (usually dramatic) in 
myoclonic seizure frequency or severity in 14 of 17 patients 
following perampanel addition [22–24, 26–28, 30–34, 36], 
lack of clinical success in one case [25], and onset of atypi-
cal absence seizures and non-convulsive status epilepticus 
in two patients [29].
3.5.1.3 Absence Seizures Outcomes for absence seizures 
are reported for 27 people with absence seizures associated 
with IGE in a post-hoc analysis of the RCT, in 83 people 
treated with perampanel in 9 observational studies, and two 
in case studies (N = 112; Table 3).
In a post-hoc analysis of the RCT, seizure outcomes in 
patients with absence seizures were explored [17]. Results 
were inconclusive, as the study was designed to study 
changes in PGTCS frequency and did not have sufficient 
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statistical power to identify statistically significant differ-
ences in the frequency of absence seizures between the treat-
ment arms. With small group sizes (perampanel N = 27, 
placebo N = 33), imbalance in demographic and prognostic 
factors is possible. Further, seizure frequency may be an 
appropriate outcome measure for PGTCS but cannot always 
be counted accurately for absence seizures. The median fre-
quency of absence seizures at baseline was 13.0 in the per-
ampanel group (range 0.4–1403.0 per 28 days), and 8.2 in 
the placebo group (range 0.4–572.0 per 28 days). Freedom 
from absence seizures was reported in 22.2% of patients 
(6/27) in the perampanel group and 12.1% (4/33) in the pla-
cebo group, and increased absence seizure frequency was 
observed in 29.6% (8/27; perampanel) and 45.5% (15/33; 
placebo) patients (Supplemental Tables S6 and S7, see ESM 
1) [17].
3.5.1.4 Tonic Seizures Outcomes for tonic seizures are 
reported for 48 people treated with perampanel in obser-
vational studies, and two in case studies (Appendix D, 
Supplemental Table S10, see ESM 1). The population was 
predominantly young children (from 6 months of age), up 
to young adults, with responder rates ranging from 20 to 
80% over 6 months of treatment [15]. No evidence of sei-
zure worsening emerged; one case of seizure clusters and 
status epilepticus possibly caused by pharmacokinetic inter-
actions and reduced serum levels of concomitant ASMs was 
reported [37].
3.5.1.5 Epileptic Spasms Outcomes for epileptic spasms 
are reported for 32 children treated with perampanel in four 
observational studies, and one case study (Appendix D, 
Supplemental Table S11, see ESM 1). No patients became 
free of epileptic spasms, and a 50% reduction in baseline 
seizure frequency was found in 31–67% of patients at 3–12 
months after addition of perampanel [15, 38–40].
3.5.2  Outcomes by Syndrome
3.5.2.1 IGE Overall Seizure and efficacy outcomes are 
reported for 81 patients with IGE treated with adjunc-
tive perampanel in one RCT [3], 24 patients in one non-
randomised interventional study [41], 271 patients in ten 
observational studies, and two case studies (total N = 378) 
(Appendix D, Supplemental Table  S1, see ESM 4). The 
RCT demonstrated statistically significant greater reduc-
tions in seizure frequency and higher responder rates with 
perampanel compared with placebo; due to the low risk of 
bias of this trial (see Sect. 3.3), the results from other study 
types characterised by higher sources of bias have not been 
synthesised here for IGE overall. Full outcomes for all study 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Perampanel in Generalised Seizures
3.5.2.2 Juvenile Myoclonic Epilepsy Outcomes in JME are 
reported in 91 people from four observational studies and 
one case study (total N = 92, Table 4). The largest of these 
included 60 patients with JME, of whom 61.7% were free 
of all seizures at 12 months and for the previous 6 months 
(37/60; Table  4). The seizure-free rate was 61.9% for 
PGTCS (26/42), 68.2% for myoclonic seizures (30/44), and 
56.3% for absence seizures (30/44). AEs were reported by 
46.7% (28/60), and led to discontinuation in 10.0% (6/60) 
(Supplemental Table S1, see ESM 4). Results from smaller 
studies were broadly consistent, with high rates of seizure 
freedom (Table 4).
3.5.2.3 Absence Epilepsies Outcomes with perampanel are 
reported in 43 people with absence epilepsy syndromes in 
two observational studies [14, 42] (Supplemental Table S12, 
see ESM 1). The largest cohort was 37 patients aged ≥ 12 
years (N = 21with JAE, N = 10 with CAE, and N = 6 with 
adult-onset absence epilepsy) [14]. In these 37 patients, 
PGTCS frequency was reduced by 71.4% from baseline at 
1 year after addition of perampanel, and 51.4% of patients 
(19/37) were free of all seizures at 12 months and since a 
6-month visit (67.9% [19/28] free of PGTCS, 33.3% [1/3] 
free of myoclonic, and 48.4% [15/31] free of absence sei-
zures).
3.5.2.4 Progressive Myoclonic Epilepsies Outcomes with 
perampanel are reported in 59 patients with progressive 
myoclonic epilepsies in two non-randomised interventional 
studies [11, 12], 45 patients in five observational studies, 
and 14 patients in case studies (total N = 118) (Table 5). 
Reductions in myoclonic seizures frequency and severity 
were seen across study types and across different aetiolo-
gies, including Lafora disease [12, 43] and Unverricht–Lun-
dborg disease [19]; reductions in PGTCS were also often 
reported. Considering the uncontrolled nature of these stud-
ies and different populations and settings, results are rea-
sonably consistent with meaningful response in 50–80% of 
patients (Table 5).
3.5.2.5 Dravet Syndrome Outcomes with perampanel are 
reported in 13 people with Dravet syndrome in three obser-
vational studies (Supplemental Table  S13, see ESM 1). 
Approximately 50% of patients experienced a ≥ 50% reduc-
tion in overall seizure frequency, and reductions were also 
reported in individual seizure types (PGTCS, clonic, myo-
clonic and atypical absence) [15, 21, 40]. Seizure worsening 
appears rare, with ≥50% increase in seizure frequency seen 
in 0/10 patients [21] and 1/2 patients [40].
3.5.2.6 Lennox‑Gastaut Syndrome Outcomes with peram-
panel are reported in 21 patients with LGS in observational 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Perampanel in Generalised Seizures
small studies, seizure responder rates ranged from 0/1 [15] 
to 6/6 [44].
3.5.2.7 West Syndrome Outcomes with perampanel are 
reported in five patients with West syndrome across two 
observational studies (Supplemental Table  S15, see ESM 
1). None of the participants were considered responders, 
and seizure frequency increased by ≥ 50% in one of the 
three patients included in one study [40].
4  Discussion
4.1  Summary of Evidence
The studies identified in this comprehensive review of the 
literature confirmed the effectiveness of add-on perampanel 
in the control of PGTCS in patients aged ≥ 12 years with 
IGE and suggested its potential role in the treatment of dif-
ferent generalised seizure types and syndromes.
Pronounced reduction or abolition of PGTCS was 
reported in epilepsy syndromes other than IGE, including 
PMEs, and the highest rates of seizure response and seizure 
freedom were observed among patients with JME. Adjunc-
tive perampanel was particularly effective in the control 
of myoclonic seizures in the context of JME; clinically 
meaningful reductions in myoclonic seizures frequency and 
severity were also seen in patients with PMEs across dif-
ferent aetiologies, including Lafora disease and Unverricht-
Lundborg disease. Adjunctive perampanel was also useful 
in the treatment of absence seizures in the context of IGE; 
the size of treatment effect was generally smaller than that 
observed for myoclonic seizures, but estimates were based 
on fewer patients.
Data for tonic seizures as well as for epileptic encepha-
lopathies like Dravet syndrome and LGS relied upon very 
small cohorts of patients and no firm conclusions can be 
drawn. However, we found no reasons to recommend against 
a therapeutic trial of adjunctive perampanel in these patients, 
particularly considering the severity of these syndromes and 
the limited therapeutic options available. Results in West 
syndrome and epileptic spasms were mixed, and both the 
limited sample sizes and unclear measurements of clinical 
outcomes, including the lack of information on EEG pattern 
and resolution of hypsarrhythmia, need to be acknowledged.
Importantly, no evidence emerged to suspect any asso-
ciations between perampanel and seizure aggravation in 
generalised epilepsies. Some individuals did experience 
increased frequency or severity of seizures after addition of 
perampanel, but in the context of larger numbers of patients 
reporting improvement. Causality regarding seizure wors-
ening cannot be proved in observational studies due to the 
natural variability in seizure course, possible changes in 
concomitant medications, and concurrent illness; these and 
other factors able to exacerbate seizure frequency and sever-
ity were not addressed in individual reports.
The tolerability profile was consistent with that reported 
in RCTs of adjunctive perampanel in patients with focal sei-
zures and with PGTCS—somnolence, dizziness/unsteadi-
ness, irritability, and altered behaviour were the most com-
monly reported AEs. Although rates of discontinuation 
due to AEs were not often reported for generalised seizure 
populations, retention rates were typically > 70% across the 
studies and suggested that adjunctive perampanel was over-
all well tolerated.
There is an emerging neurophysiological rationale to 
support a broad-spectrum effect of perampanel in epilepsy. 
A recent study explored the effect of perampanel on excit-
ability in cortico-subcortical networks, by measuring high-
frequency oscillations of somatosensory evoked potentials 
in 15 people with epilepsy [53]. A reduction was observed 
in the area of total high-frequency oscillations, mainly on the 
early burst related to thalamo-cortical pathways. This sug-
gests a mechanism via which antagonism of AMPA recep-
tors by perampanel could be broadly effective across various 
seizure types in epilepsy.
4.2  Strengths and Limitations
The strengths of this systematic review include the com-
prehensive search strategy aimed to include studies of all 
types, ‘grey literature’ represented by non-peer-reviewed 
conference abstracts, and ongoing studies identified through 
clinical trials registries. Results from individual studies were 
often reported multiple times, and our careful checks for 
‘encore’ conference abstracts and exclusion of interim data 
that was superseded by later reports ensured that the major-
ity of evidence we gathered came from unique patients. 
Inclusion of data from conference abstracts and unpublished 
studies posted in clinical trials registries minimised the risk 
of (positive) publication bias.
A major limitation is that the certainty of the evidence 
provided by observational, non-controlled, and non-
randomised studies is low due to many sources of bias, 
including the placebo effect, natural fluctuations in seizure 
frequency, lack of a control group and blinding/masking, 
overestimation of efficacy and regression to the mean. 
Definitive conclusions on comparative safety and efficacy 
can only be obtained through well-designed RCTs. However, 
real-world evidence does have a place in healthcare decision 
making. For example, data from observational studies and 
case reports can help to extrapolate findings from clinical 
trials to more representative patient populations, including 
those who are often excluded from clinical trials. Real-world 
evidence can also give a ‘signal’ of effectiveness in seizures 
and epilepsy types that are often excluded from clinical trial 
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populations, such as rare and serious epilepsies like PMEs, 
or patients with intellectual disability. Ideally, RCTs will 
follow this hypothesis generation to formally assess efficacy 
and safety. So our summary of evidence should be used not 
as an indication of what seizure outcomes could be expected 
in other patients with similar seizure types, but to indicate 
general populations where a therapeutic trial of perampanel 
may be warranted.
Another limitation was the heterogeneity in populations, 
outcome measures and definitions used in the identified stud-
ies, which did not allow a quantitative data synthesis and 
also hampered the qualitative analysis. In particular, seizure 
freedom was sometimes reported in the completer popula-
tion and sometimes in the full intent-to-treat population, 
with unclear definitions of ‘freedom’. The reporting of find-
ings from observational studies was often of poor quality; 
outcome data were provided for subgroups that had no cor-
responding demographic data and sometimes no N-numbers, 
settings of the studies were often not given, denominators/
populations were often undefined (e.g. completer popula-
tion or intent-to-treat population) and ‘response’ was some-
times not defined. These issues highlight the need for better 
and consistent outcome reporting in real-world evidence 
in epilepsy, highlight a lack of familiarity with applicable 
reporting standards (e.g. STROBE), and reflect the lack of a 
specific reporting standard that matches these single-cohort, 
non-comparative, observational study designs.
5  Conclusions
Management of epilepsy can be particularly challenging 
when the presenting seizure type is unclear or more seizure 
types coexist. In such situations, broad-spectrum ASMs are 
a rational choice. Furthermore, many patients have general-
ised seizure types that are not well represented in RCTs, and 
treatment decisions often have to be made in the absence of 
Class I evidence.
By gathering all currently available evidence, including 
observational real-world data, we can begin to look for pat-
terns and identify seizure types where adjunctive use of per-
ampanel might be beneficial and justifies further research. 
The data we have collected suggest, although with weak 
certainty due to the observational nature and high risk of 
bias of most of the included studies, that perampanel can be 
effective and tolerated in multiple generalised seizure types 
in absence of any suspicion of seizure worsening or aggra-
vation (see summary video in ESM 3). In addition to the 
high-quality evidence already supporting the effectiveness 
of perampanel in PGTCS and in focal seizures, these data 
play in favour of its potential as a broad-spectrum ASM. 
Therapeutic trials of adjunctive perampanel may be particu-
larly warranted in patients with JME, myoclonic seizures 
associated with PMEs and absence seizures. We encour-
age well-designed interventional studies with perampanel 
in these epilepsies to provide additional and more robust 
findings and to better delineate the antiseizure activity and 
profile of perampanel.
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